Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity
- PMID: 7545296
- PMCID: PMC41124
- DOI: 10.1073/pnas.92.18.8200
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity
Erratum in
- Proc Natl Acad Sci U S A 1995 Nov 7;92(23):10818
Abstract
In the tumor-bearing host, T cells invariably fail to induce a clinically significant antitumor immune response. Although model systems support the existence of tumor peptide antigens, the molecular interactions critical for antigen presentation by the tumor cell remain unresolved. Here, we demonstrate that human follicular lymphoma cells are highly inefficient at presenting alloantigen despite their strong expression of major histocompatibility complex and low-to-intermediate expression of some adhesion and B7 costimulatory molecules. Activation of follicular lymphoma cells via CD40 induces or up-regulates both adhesion and B7 costimulatory molecules essential to repair this defect. More importantly, once primed, alloreactive T cells efficiently recognize unstimulated follicular lymphoma cells. Thus, correction of defective tumor immunity requires not only expression of major histocompatibility complex but also sufficient expression of multiple adhesion and costimulatory molecules.
Similar articles
-
Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.Eur J Immunol. 1998 Jan;28(1):90-103. doi: 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5. Eur J Immunol. 1998. PMID: 9485189
-
Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells.Br J Haematol. 1999 Jul;106(1):64-70. doi: 10.1046/j.1365-2141.1999.01474.x. Br J Haematol. 1999. PMID: 10444164
-
Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.Blood. 1996 Jul 1;88(1):41-8. Blood. 1996. PMID: 8704200
-
From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.Leuk Lymphoma. 2000 Jul;38(3-4):247-63. doi: 10.3109/10428190009087016. Leuk Lymphoma. 2000. PMID: 10830732 Review.
-
T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.Crit Rev Immunol. 2017;37(2-6):463-481. doi: 10.1615/CritRevImmunol.v37.i2-6.130. Crit Rev Immunol. 2017. PMID: 29773030 Review.
Cited by
-
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.Cancer Immunol Immunother. 2013 Feb;62(2):347-57. doi: 10.1007/s00262-012-1331-4. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926059 Free PMC article.
-
B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement.J Exp Med. 1998 Mar 2;187(5):753-62. doi: 10.1084/jem.187.5.753. J Exp Med. 1998. PMID: 9480985 Free PMC article.
-
Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect.Immunology. 2014 Nov;143(3):428-37. doi: 10.1111/imm.12320. Immunology. 2014. PMID: 24834964 Free PMC article.
-
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.J Exp Med. 2003 May 19;197(10):1279-89. doi: 10.1084/jem.20030044. Epub 2003 May 12. J Exp Med. 2003. PMID: 12743171 Free PMC article.
-
Therapeutic vaccines for non-Hodgkin B-cell lymphoma.Clin Transl Oncol. 2008 Sep;10(9):543-51. doi: 10.1007/s12094-008-0249-4. Clin Transl Oncol. 2008. PMID: 18796371 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials